Acamprosate

Oral
Alcohol abstinence

CrCl (mL/min)	Dosage
<30	Contraindicated.
30-50	Initially, 333 mg tid.

Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).

May be taken with or without food. Swallow whole & do not chew/crush/cut. Consult product literature for specific recommendations.

Severe renal impairment (CrCl <30 mL/min).

Patient with suicidal ideation. Moderate renal impairment (CrCl 30-50 mL/min) and severe hepatic impairment (Child-Pugh class C). Elderly. Pregnancy and lactation.

Significant: CNS depression; suicidal thinking or behaviour.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain, flatulence.
Reproductive system and breast disorders: Frigidity, impotence.
Skin and subcutaneous tissue disorders: Pruritus, maculopapular rash.

PO: C

This drug may cause CNS depression, if affected, do not drive or operate machinery.

Monitor renal function and weight. Assess for signs of suicidal ideation.

Symptoms: Diarrhoea. Management: Symptomatic and supportive treatment.

Increased plasma concentration with naltrexone.

Decreased absorption with food.

Description:
Mechanism of Action: Acamprosate is a homotaurine analogue which interacts with glutamate and γ-aminobutyric acid (GABA) neurotransmitter systems in the CNS. It is believed to act by increasing the activity of the GABAergic system and decreasing the activity of glutamate within the CNS. Additionally, it restores the balance between GABA and glutamate activities which appear to be disrupted in alcohol use disorder.
Pharmacokinetics:
Absorption: Moderate, slow and sustained absorption from the gastrointestinal tract. Decreased absorption with food. Bioavailability: Approx 11%. Time to peak plasma concentration: 3-8 hours.
Distribution: Crosses the blood-brain barrier. Volume of distribution: Approx 1 L/kg.
Excretion: Via urine (as unchanged drug). Elimination half-life: 20-33 hours.

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 71158, Acamprosate. https://pubchem.ncbi.nlm.nih.gov/compound/Acamprosate. Accessed Feb. 26, 2024.

Store between 20-25°C.

Thuốc hỗ trợ cai nghiện

N07BB03 - acamprosate ; Belongs to the class of drugs used in the management of alcohol dependence.

Acamprosate Calcium Enteric-coated Tablet, Delayed Release (Mylan Pharmaceuticals Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 06/11/2023.

Anon. Acamprosate Calcium. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 06/11/2023.

Anon. Acamprosate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 06/11/2023.

Buckingham R (ed). Acamprosate Calcium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/11/2023.

Campral EC (Merck Serono Limited). MHRA. https://products.mhra.gov.uk. Accessed 06/11/2023.

Joint Formulary Committee. Acamprosate Calcium. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/11/2023.